HOME >> MEDICINE >> NEWS
Pathway may provide target for treating chronic pain

of how and why they become active.

In Nature last year, Zhuo and colleague Ping Li, M.D., a research associate in anesthesiology, reported that they could identify silent synapses by monitoring electrical responses of individual neurons. After these synapses were awakened, they remained active and able to relay painful sensory information to the brain even after the painful stimulus was gone.

In those experiments, the researchers showed that the silent synapses could be activated both by strong pain signals and by messages from a brain region called the rostroventral medulla (RVM), which sends chemical signals to the dorsal horn of the spinal cord. But little was known about what happens inside a nerve cell when a silent synapse is activated.

In the current study, Zhuo and colleagues found that activation of silent synapses involves an interaction between AMPA receptors and a protein called glutamate receptor interacting protein (GRIP).

"One hypothesis is that GRIP binds to the cell at an AMPA receptor site inside of the cell," Zhuo said. "Then, under certain conditions, the receptor moves itself to the synaptic part of the neuron. That movement activates the formerly silent synapse."

Receptors at synapses receive messages from other neurons. AMPA receptors are sensitive to a brain chemical called glutamate.

"AMPA receptors are highly dynamic," said co-investigator Morgan Sheng, M.D., Ph.D., associate professor of neurobiology at Massachusetts General Hospital and Harvard Medical School and assistant investigator with the Howard Hughes Medical Institute. "They can be recruited to and removed from the synapse. It's actually a marvelously simple way to regulate synaptic strength. You silence a synapse by taking away receptors and strengthen it by adding more receptors."

Zhuo compares the process to an overnight courier service. Each evening, many packages come in. But the next morning, those packages go back out, allowing the office to m
'"/>

Contact: Jim Dryden
dryden@medicine.wustl.edu
314-286-0110
Washington University School of Medicine
17-Oct-1999


Page: 1 2 3

Related medicine news :

1. Cell Pathways Aptosyn™ (exisulind) shows continuing long-term prevention of colon polyps in FAP patients
2. Study provides new estimates of the causes of child mortality worldwide
3. Researchers say breast cancer in Africa may provide clues to the disease in African-Americans
4. End AIDS drug waiting lists, HIV care providers tell policymakers
5. Artery clearing system does not provide benefit for patients undergoing PCI
6. Newly identified gene cluster on mouse X chromosome provides insights into fertility
7. University of Washington joins new Autism Treatment Network to provide better medical services
8. Rat whisking may provide insight into debilitating eye disorder
9. Researchers hope monkeys can provide new insights into depression
10. AGI and USGS provide unique tsunami disaster relief
11. New ITN Scholars Program provides junior faculty opportunity to develop clinical trials expertise

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Pathway may provide target for treating chronic pain

(Date:7/30/2015)... ... 30, 2015 , ... Zaca Life has created Recovery Chewable ... water needed, the refreshing berry-flavored tablets are the perfect travel companion. , “We ... that may help with body detoxification, protection and hydration,” said Mark Aleks, Zaca ...
(Date:7/30/2015)... ... July 30, 2015 , ... The American Telemedicine Association (ATA) ... Tradeshow focused exclusively on telemedicine, telehealth and mHealth. The meeting, expected to attract ... take place May 14-17, 2016 in Minneapolis, MN. , ATA’s annual meeting attracts ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... Orange, Riverside, Los Angeles, and San Bernardino counties, today announced that Dr. Michael ... Care Administrator. Dr. Demoratz is a strong proponent of early access to palliative ...
(Date:7/30/2015)... ... 2015 , ... The Beryl Institute announces its sixth annual ... Patient Experience Institute, these offerings reinforce the commitment to help frame and expand ... the experience movement, and provide information and research to support expanded focus and ...
(Date:7/30/2015)... ... July 30, 2015 , ... The Mesothelioma Applied Research ... Patient Registry Act of 2015’. The bill was introduced in Congress yesterday by ... Betty McCollum (D-MN), Joe Kennedy (D-MA), and Leonard Lance (R-NJ). The purpose of ...
Breaking Medicine News(10 mins):Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 2Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 3Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 3Health News:Bill to Create Patient Registry for Deadly Cancer Introduced in Congress 2
(Date:7/29/2015)... July 30, 2015 Roche (SIX: RO, ROG; ... cobas® EGFR Mutation Test v2 for Premarket Approval ... (FDA), as a companion diagnostic test for AZD9291, ... cancer patients with an acquired resistant mutation.  ... who have adenocarcinoma with tumor containing an EGFR ...
(Date:7/29/2015)... 2015  Unilife Corporation ("Unilife" or the "Company") (NASDAQ: ... and supplier of injectable drug delivery systems, today announced ... the Company with flexibility and control to support its ... an equity purchase agreement for up to $45 million ... Chicago -based institutional investor, which provides the ...
(Date:7/29/2015)... BERKELEY, Calif. , July 29, 2015 /PRNewswire/ ... of the Daiichi Sankyo Group, announced today that ... clinical trial results demonstrating that the investigational drug, PLX3397, ... in most patients with tenosynovial giant cell tumor (TGCT), ... tendon sheath. Following phase 1 dose-escalation, which ...
Breaking Medicine Technology:Roche submits filing to FDA for companion diagnostic for non-small cell lung cancer drug therapy 2Roche submits filing to FDA for companion diagnostic for non-small cell lung cancer drug therapy 3Unilife Announces Multifaceted Financing Strategy 2Unilife Announces Multifaceted Financing Strategy 3Unilife Announces Multifaceted Financing Strategy 4Unilife Announces Multifaceted Financing Strategy 5Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 2Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 3Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 4Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 5
Cached News: